

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandria, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/600,584	06/19/2003	Robert W. Blakesley	55670DIV(45858)	5497	
	7590 03/31/200 NGELL PALMER & F	EXAM	EXAMINER		
P.O. BOX 55874			BABIC, CHRISTOPHER M		
BOSTON, MA	. 02205	ART UNIT	PAPER NUMBER		
		1637			
			MAIL DATE	DELIVERY MODE	
			03/31/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/600,584	BLAKESLEY ET AL.	
Examiner	Art Unit	
CHRISTOPHER M. BABIC	1637	

	CHRISTOPHER W. BABIC	1037					
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress				
THE REPLY FILED 23 March 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
<ol> <li>X he reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance, (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:</li> </ol>	the same day as filing a Notice of a replies: (1) an amendment, affidavite al (with appeal fee) in compliance FR 1.114. The reply must be filed	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request				
The period for reply expiresmonths from the mailing     The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	g date of the final rejection	n.				
Examiner Note: If box 1 is checked, check either box (a) or ( MONTHS OF THE FINAL REJECTION. See MPEP 706.07(i		FIRST REPLY WAS FI	LED WITHIN TWO				
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filled is the date for purposes of determining the period to the under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	ension and the corresponding amount of hortened statutory period for reply origing than three months after the mailing date	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as				
2. The Notice of Appeal was filed on 23 March 2009. A brief	in compliance with 37 CFR 41.37	must be filed within tw	o months of the				
date of filing the Notice of Appeal (37 CFR 41.37(a)), or an Since a Notice of Appeal has been filed, any reply must be	ny extension thereof (37 CFR 41.37	7(e)), to avoid dismiss	al of the appeal.				
AMENDMENTS							
<ol> <li>The proposed amendment(s) filed after a final rejection, t</li> <li>They raise new issues that would require further cor</li> </ol>			cause				
(b) ☐ They raise the issue of new matter (see NOTE below		E below),					
<ul> <li>(c) ☐ They are not deemed to place the application in bett appeal; and/or</li> </ul>		ducing or simplifying th	ne issues for				
(d) They present additional claims without canceling a c	corresponding number of finally reje	ected claims.					
NOTE: (See 37 CFR 1.116 and 41.33(a)).							
4. The amendments are not in compliance with 37 CFR 1.12	1. See attached Notice of Non-Cor	mpliant Amendment (I	PTOL-324).				
5. Applicant's reply has overcome the following rejection(s):	See Continuation Sheet.						
<ol> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ol>	owable if submitted in a separate, t	timely filed amendmer	nt canceling the				
7. X For purposes of appeal, the proposed amendment(s): a) [		I be entered and an e	xplanation of				
how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:	ided below or appended.						
Claim(s) allowed:							
Claim(s) objected to:							
Claim(s) rejected: <u>26.27.33-37 and 39-48</u> .							
Claim(s) withdrawn from consideration:  AFFIDAVIT OR OTHER EVIDENCE							
The affidavit or other evidence filed after a final action, but	before or on the date of fling a bla	tion of Annualill not	be entered				
<ul> <li>because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ul>							
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appear and was not earlier presented. Se	al and/or appellant fail ee 37 CFR 41.33(d)(1	s to provide a ).				
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.				
11. The request for reconsideration has been considered but	does NOT place the application in	condition for allowan	ce because:				
12. Note the attached Information Disclosure Statement(s). (13. Other: See Continuation Sheet.	PTO/SB/08) Paper No(s)						
	/Kenneth R Horlick/						
	Primary Examiner, Art U	nit 1637					

Continuation of 5. Applicant's reply has overcome the following rejection(s): 1) Rejection of claims 26, 27, 33-37, and 39-42 over 35 USC 112, 2nd paragraph; and 2) Rejection of claims 26,27,33,34,37,39,41, and 42 under 35 USC 102(b) over Fujishiro.

Continuation of 13. Other: Applicant's amendments and supporting evidence have been fully considered but are not sufficient to over come the rejection of claims 26,27,33-37 and 39-48 under 35 USC 103(a) over Rogers, Burgoyne, and Kahn.

Applicant's arguments and supporting affidavit reiterate arguments already of record presenting summarily that, "Plasmid DNA behaves differently from genomic DNA based on its size and its structure. It would not be expected that less complex DNA would interact with a solid matrix in the same manner as genomic DNA, so it would not be intuitive that plasmid DNA could be isolated on a solid matrix."

As presented previously, Rogers clearly shows that FTA® medium ruptures bacterial cell walls such that PCR reagents can effectively amplify cellular DNA. Thus, it is clear that once applied to FTA® medium, bacterial cell walls are disrupted such that cellular DNA is liberated from the cell. Furthermore, Burgoyne clearly shows that pure plasmid DNA can be eluted from FTA® eldium. Thus, it is clear that the circular structure of bacterial plasmid DNA does not interfere with or prevent elution from FTA® medium. Given these teachings, a skilled artisan would have a reasonable expectation of success when attempting to elute plasmid DNA from a bacterial culture on FTA® medium. Applicant is reminded that obviousness does not require absolute predictability (see MPEP 2143.02, for example).

Thus, the rejection is maintained.